Cabazitaxel
- Atc Codes:L01CD04
- CAS Codes:183133-96-2
- PHARMGKB ID:183133-96-2
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
North America
USA: Jevtana kit.
Drug combinations
Chemistry
Cabazitaxel: C~45~H~57~NO~14~ C~3~H~6~O. Mw: 894.01 (for the acetone solvate)/ 835.93 (for the solvent-free). (1)(2a,5b,7b,10b,13a)-4-acetoxy-13-({(2R,3S)-3-[(tertbutoxycarbonyl) amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate-propan-2-one(1:1); (2) 1-hydroxy-7β,10β-dimethoxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-{[(tertbutoxycarbonyl]amino}-2-hydroxy-3-phenylpropanoate]. CAS-183133-96-2.
Pharmacologic Category
Antineoplastic Agents; Plant Alkaloids and Other Natural Products; Microtubule Inhibitor. (ATC-Code: L01CD04).
Mechanism of action
Binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the inhibition of mitotic and interphase cellular functions.
Therapeutic use
Indicated in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
Pregnancy and lactiation implications
May cause fetal harm when administered to a pregnant woman. Not recommended during lactation.
Unlabeled use
Contraindications
History of severe hypersensitivity to cabazitaxel or polysorbate 80. Neutrophil counts of ≤1.500/mm^3^.
Warnings and precautions
Neutropenic deaths have been reported. Severe hypersensitivity reactions can occur (infusion should be discontinued immediately if hypersensitivity is observed). Gastrointestinal symptoms (nausea, vomiting, diarrhea) may occur; mortality related to diarrhea has been reported (if experiencing Grade 3 diarrhea, dosage should be modified). Renal failure, including cases with fatal outcomes, has been reported. Patients 65 years of age were more likely to experience fatal outcomes not related to disease progression and certain adverse reactions, including neutropenia and febrile neutropenia. Should not be given to patients with hepatic impairment (hepatic impairment is likely to increase cabazitaxel concentrations). Can cause fetal harm when administered to pregnant women.